Immunotherapy combo shows promise against stomach cancer in early trial

NCT ID NCT04221555

Completed Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested adding the immunotherapy drug durvalumab to a standard chemotherapy regimen (docetaxel, oxaliplatin, S-1) before and after surgery in 68 patients with resectable stomach or gastroesophageal junction cancer. The main goal was to see how many patients had a complete disappearance of the tumor after treatment. The study also tracked how long patients remained cancer-free after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug) plus docetaxel, oxaliplatin, and S-1 (chemotherapy drugs)
What this could lead to: If successful, this combination could improve the chance of eliminating the tumor before surgery and delay cancer return after surgery.
What could go wrong: This is a small, early-phase trial (68 people) with no control group, so results may not be definitive. Immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Asan Medical Center

Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.